• 검색 결과가 없습니다.

Bone Mineral Density After Transitioning From Denosumab to Alendronate

N/A
N/A
Protected

Academic year: 2021

Share "Bone Mineral Density After Transitioning From Denosumab to Alendronate"

Copied!
10
0
0

로드 중.... (전체 텍스트 보기)

전체 글

Loading

수치

Fig. 3  shows BMD responses for individual partici- partici-pants throughout the study for the groups that lost,  main-tained, and gained BMD during year 2 on alendronate
Table 2.  Participant Characteristics at Study Baseline
Figure 2.  BTM percentage change from baseline with denosumab in year 1 and alendronate in year 2. Data show mean and interquartile range
Figure 3.  Individual participant BMD changes for groups that lost, maintained, or gained BMD in year 2 on alendronate
+2

참조

관련 문서

The porous PCL scaffolds produced from the gas foaming and salt leaching and plasma surface treatment are suitable for potential applications in bone

Methods to overcome insufficient bone due to poor bone quality, the pneumatization of a maxillary sinus and other anatomical limitations of implant placement

Histopathologic findings of control group at 4 weeks show little bone- implant contact (BIC) around the implant (asterisks) and new-bone formation in the defect

Purpose: We investigated the impact of treatment on electroencephalogram (EEG) findings, and determined efficacy of antiepileptic drugs according to EEG findings

Diagnosis and Treatment of Oral admidstrated Bisphosphonate-related osteonecrosis of the jaw.. and implantation

Approved clinical use of bone marrow stem cells for myocardial infarction treatment... Cardiac

Biochemical markers of bone turnover can be classified according to the process that underlie in markers of bone formation, products of the osteoblast

of mineralized cancellous bone allograft(Puros) and anorganic bovine bone matrix(Bio-oss) for sinus augmentation: Histomorphometry at 26 to 32 weeks after